ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Entadfi
December 14, 2021Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer... -
Veru initiates enrolment in Phase III trial of sabizabulin for Covid-19
May 20, 2021Veru has enrolled the first subject in Phase III clinical trial of sabizabulin to treat hospitalised Covid-19 patients who are at high risk for acute respiratory distress syndrome (ARDS). -
Veru to progress Covid-19 drug into Phase III study
March 03, 2021Veru is set to advance its drug VERU-111 into a Phase III registration clinical study on hospitalised high-risk Covid-19 patients for obtaining clinically meaningful benefits in the Phase II clinical trial. -
Veru reports positive data from Phase II Covid-19 drug trial
February 10, 2021Veru has reported positive efficacy and safety results from Phase II clinical trial of an oral drug, VERU-111, in hospitalised Covid-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS).
Pharma Sources Insight January 2025
